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Background and objectives Several sources of haematopoietic stem cells have
been used for static culture of megakaryocytes to produce platelets in vitro. This
study compares and characterizes platelets produced in shear flow using precur-
sor cells from either umbilical (UCB) or adult peripheral blood (PB).
Materials and methods The efficiency of platelet production of the cultured cells
was studied after perfusion in custom-built von Willebrand factor-coated
microfluidic flow chambers. Platelet receptor expression and morphology were
investigated by flow cytometry and microscopy, respectively.
Results Proliferation of stem cells isolated out of UCB was significantly higher
(P < 00001) compared to PB. Differentiation of these cells towards megakary-
ocytes was significantly lower from PB compared to UCB where the fraction of
CD42b/CD41 double positive events was 44 – 9% versus 76 – 11%, respectively
(P < 00001). However, in vitro platelet production under hydrodynamic condi-
tions was more efficient with 74 platelet-like particles per input cell from PB
compared to 42 from UCB (P = 002). The percentage of events positive for
CD42b, CD41 and CD61 was comparable between both stem cell sources. The
mean number of receptors per platelet from UCB and PB was similar to that on
blood bank platelets with on average 28 000 CD42b, 57 000 CD61 and 5500
CD49b receptors. Microscopy revealed platelets appearing similar to blood bank
platelets in morphology, size and actin cytoskeleton, alongside smaller fragments
and source megakaryocytes.
Conclusion This characterization study suggests that platelets produced in vitro
under flow either from UCB or from PB share receptor expression and morphol-
ogy with donor platelets stored in the blood bank.
Key words: haematopoiesis, megakaryopoiesis, platelets, stem cells, tissue
engineering.
Introduction
Transfusion of platelet concentrates (PC) can be a life-
saving treatment for patients suffering from thrombocy-
topenia [1]. Platelet inventory management is a major
challenge because donor attendance is unpredictable and
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the demand for PC is increasing, in addition to the lim-
ited shelf life of PC [2, 3]. This has stimulated researchers
to investigate in vitro production of platelets as an alter-
native to donor-derived PC. The platelet moreover offers
an ideal model cell for tissue engineering with limited
risks of carcinogenesis because platelets are anucleate
and thus do not replicate and the final product could be
irradiated using low intensity gamma irradiation before
transfusion. [4, 5].
Platelets are produced by megakaryocytes (MK) that
reside outside the blood vessel but protrude cellular
extensions that release (pro)platelets in circulation [6, 7].
When this physiological production process can be mim-
icked in vitro, an attractive alternative for the current pla-
telet blood banking chain is offered. The ideal unlimited
cell source for MK is a self-renewable embryonic [8] or
induced pluripotent stem cell [9, 10] or immortalized or
chemically defined MK cell line [5, 11]. However, research
into the platelet production process currently still requires
isolated primary haematopoietic stem cells (HSC) until
limitations of the current self-renewable cell sources are
overcome. Umbilical cord blood (UCB) is often used as
HSC source [12–16] but requires specialized access and is
thus not always available to research teams. Leuko-deple-
tion filters as a waste product of whole blood donations
therefore offer an attractive alternative source [17]. But
even simpler, buffy coats from routine whole peripheral
blood donations (PB) are available daily in many blood
banks in Europe and may be source material for stem cell
isolation [18] and in vitro platelet production on a
research scale [19].
In this study, the efficiency and quality of in vitro pla-
telet production in a microfluidic flow chamber chip
coated with von Willebrand factor (VWF) [20] was evalu-
ated for cells derived from UCB compared to PB. The pla-
telets were studied by differential interference contrast
(DIC) and fluorescent microscopy and flow cytometry.
Data were compared to standard blood bank platelets
(bPLT).
Materials and methods
Isolation of CD34+ haematopoietic stem cells
Human HSC were obtained from UCB or from buffy coats
isolated from PB. The research protocols were approved
by ethical committees of Ghent University Hospital
(2016/0448) and Antwerp University Hospital
(B300201420404). Isolation of HSC from UCB was by
selection of CD34+ cells using an immunomagnetic cell-
sorting system (QuadroMACS, Miltenyi Biotech, Bergisch
Gladbach, Germany) according to the manufacturer’s
instructions. Briefly, red blood cell lysis was induced with
2% dextran (w/v) before performing density-gradient
centrifugation using ficoll (970 g – 20 min – room tem-
perature (RT)). The mononucleated cell layer was aspi-
rated and washed. Total nucleated cell number was
determined in a Malassez haemocytometer. The nucleated
cells were resuspended to 108 cells in 300 ll phosphate-
buffered saline (PBS) (15 mM KH2PO4, 137 mM NaCl, 27
mM KCl and 8 mM Na2HPO4 at pH 74) supplemented
with 2 mM ethylenediaminetetraactic acid (EDTA) and
05% bovine serum albumin (BSA) (w/v) before addition
of 100 ll anti-CD34 labelled magnetic beads and 100 ll
Fc-receptor blocking agent per 108 cells. Cells were incu-
bated for 90 min at 4°C during constant agitation before
removal of unbound cells by centrifugation (300 g –
10 min – RT) and resuspension in PBS with EDTA and
BSA. Bound CD34+ cells were collected and counted in
the Malassez haemocytometer. After isolation, the cells
were cryopreserved at 05–10 9 106 cells per mL in fetal
bovine serum and 10% (v/v) dimethylsulphoxide at -
80°C (≥24 h) before transfer to our liquid nitrogen (-
196°C) long time storage facility. Three buffy coats pre-
pared from voluntary whole blood donations by the Bel-
gian Red Cross-Flanders Blood Service were pooled prior
to isolation of HSC according to the protocol described
previously. Whole blood donations contain approximately
14% (v/v) citrate-phosphate-dextrose-acid as anticoagu-
lant. After storage overnight at RT, whole blood dona-
tions were centrifuged (4556 g – 13 min – RT).
Automated separators were used for separation into red
blood cell concentrate, plasma and a buffy coat. Excess
buffy coats not used for platelet concentrate preparation
were used in this work. The number of magnetic beads
used per total number of nucleated cells was lower, and
additional washing steps were used compared to isolation
from UCB to compensate for the low ratio HSC versus
total nucleated cells in PB [21].
Cell culture towards megakaryocytes
Cryopreserved HSC were thawed in a 37°C water bath
before addition of 10 ml prewarmed HP01 medium
(Macopharma, Tourcoing, France) and centrifugation
(300 g – 10 min – RT). HSC were resuspended in HP01
supplemented with 10 nM thrombopoietin peptide (TPO,
Sigma-Aldrich, Saint Louis, MO), 25 ng/ml stem cell
factor (SCF, Miltenyi Biotech) and 2 ng/ml interleukin 3
(IL3, Miltenyi Biotech) and were seeded at 300 000
cells/ml for 6 days of expansion. On day 7 (D7), cells
were split at 500 000 cells/ml in HP01 containing
50 nM TPO and 2 ng/ml SCF for differentiation towards
MK. All cells were harvested on D12 and subjected to
BSA gradient centrifugation for removal of small parti-
cles [22].
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Definition of platelets and cultured cells
In this manuscript, the term (input) cells is used for parti-
cles with a diameter ≥ 7 lm counted in a Malassez
haemocytometer. Particles ≤ 7 lm are called platelet-like
particles (PLP). Size of particles was measured using the
analytical software tools for microscopy (Zen 2, Blue edi-
tion, Carl Zeiss). The same term (PLP) is also used for flow
cytometry events appearing inside a polygon gate set as a
contour around bPLT as source material [23] (Figs S1a
and b). This polygon gate is further referred to as the
morphology gate. Particles within the morphology gate
that stain positive for both surface receptor CD42b and
CD41 (see below) were then defined as platelets (Fig S1c).
Standard blood bank platelets
Platelets from PC were used as reference material to com-
pare with in vitro platelet production and are defined as
standard blood bank platelets. The PC were prepared
according to standard blood banking methods as
described previously [24, 25], in this case by pooling of
six buffy coats. A final 65% (v/v) of additive solution
(SSP+, Macopharma, Tourcoing) was targeted.
Phenotyping by flow cytometry
Differentiation of cultured cells was determined by flow
cytometry (Attune, Life Technologies, Carlsbad, CA) on D0,
D4, D7, D10, D11 and D12. The haematopoietic precursor
lineage was determined with an antibody against CD34
(phycoerythrin (PE)-anti-CD34, BD, Biosciences, Erem-
bodegem, Belgium). Determination of MK differentiation
was with fluorescein (FITC)-labelled anti-CD42b (Life Tech-
nologies) and PE-Cy7-labelled anti-CD41 (BD Biosciences).
Cells and antibodies were incubated for 10 min in 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid buffered
saline (HBS) (10 mM HEPES, 155 mM NaCl and 1 mM
MgSO4, pH 74) at RT [26]. Expression of CD42b (GPIba),
CD41 (GPIIb) and CD61 (GPIIIa) on PLP was detected using
FITC-labelled anti-CD42b, PE-Cy7-labelled anti-CD41 and
allophycocyanin (APC)-labelled anti-CD61 (Life Technolo-
gies).The median number of CD42b, CD41 and CD49b
(GPIa) receptors per PLP was quantified using the GP screen
kit (Biocytex, Marseille, France). Threshold gates were set
including 05% of 10 000 events incubated with corre-
sponding isotype antibody negative controls.
In vitro platelet production
Microfluidic flow chamber chips were manufactured from
polydimethylsiloxane as described before [27]. One chip
(length = 173 cm) consisted of 16 parallel channels
composed of a structured network of pillars. The radius of
one pillar is 15 lm, and the distance between neighbour-
ing pillars, from centre to centre, is 85 lm. The pillars
are oriented so that the angle between the pillar array
and the flow direction of the channel is 10°. Prior to cell
perfusion, the chip was coated overnight with 40 lg/ml
purified VWF (Wilfactin, LFB Biotechnologies, France).
The perfusion experiment was performed according to
Blin et al. [27]. In brief, the harvested cell suspension on
D12 of culture was placed on an orbital shaker and was
connected to the perfusion chamber inlet and outlet by
tubing. A peristaltic pump (Watson-Marlow, Falmouth,
UK) created continuous perfusion of the cell suspension
at a wall shear rate of 1800 s-1 for two hours during
which platelets were formed. Adhering cells were visual-
ized by phase contrast microscopy at 1009 magnification
(Axio observer A1, Carl Zeiss). After perfusion, the sus-
pension was centrifuged at 110 g for 20 min to remove
MK. Next, the supernatant was centrifuged at 1240 g for
15 min to pellet the platelets.
Differential interference contrast microscopy
The morphology of PLP was determined by DIC micro-
scopy (Axio observer A1, Carl Zeiss). Cell suspensions were
resuspended in Tyrode’s washing buffer (135 mM NaCl,
27 mM KCl, 12 mM NaHCO3, 430 lM NaH2PO4, 1 mM
MgCl2, 5 mM HEPES with 01% (w/v) D-glucose and 035%
(w/v) BSA) at pH 74 before fixation with 2% (w/v)
paraformaldehyde. Fixed cells were centrifuged at 2000 g
for 20 min onto glass coverslips, coated with 01% (w/v)
poly-L-lysine (Sigma Aldrich, Saint Louis). These cover-
slips were then mounted on glass carriers. A 1009 oil
immersion objective (numerical aperture = 14) was used
to a final magnification of 10009. To control for potential
side-effects downstream of platelet production caused by
centrifugations, bPLT were subjected to the same centrifu-
gation protocol prior to preparation for DIC imaging.
Cytoskeleton staining
Actin was visualized on PLP from UCB and on bPLT by
Alexa Fluor (AF) 405 labelled-phalloidin (Invitrogen,
Carlsbad, CA). Coverslips were prepared as described
under differential interference contrast microscopy. Cells
were permeabilized with 05% (v/v) triton X-100 (Sigma
Aldrich, Saint Louis) followed by staining with 165 lM
AF405~phalloidin and mounting onto glass carriers.
Statistical analysis
Results are reported as mean with standard deviation
(SD). Comparison between stem cell sources was by two-
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tailed t-test (with Welch’s correction for unequal vari-
ances), by one-way ANOVA for comparison of mean num-
ber of receptors per PLP (Tukey’s correction for multiple
comparison) or with two-way ANOVA (Sidak’s correction
for multiple comparison) for comparison of both HSC
sources at different time points of culture. Correlation
was by Spearman’s algorithm. Statistical analyses was
performed with Prism version 7.04 (GraphPad Software
Inc., La Jolla, CA).
Results
Haematopoietic stem cell isolation, proliferation
and differentiation towards megakaryocytes
Table 1 shows that the mean number of nucleated cells in
PB was at least 4-fold higher in comparison to UCB.
However, the mean absolute number of cells isolated per
PB is 393 9 105 compared to 1697 9 105 per UCB. The
percentage of isolated cells per total nucleated cells for
UCB and PB source samples is presented in Fig. 1a. A sig-
nificantly higher (P < 00001) yield was found for UCB
(133 – 074%) compared to PB (006 – 002%). Prolifera-
tion in static culture was significantly faster for UCB-
derived HSC compared to PB (P < 00001 on D7, Fig. 1b).
As expected, proliferation decreased when the TPO, SCF
and IL3 concentration were changed on D7 (Fig. 1b).
Consequently, CD34 expression decreased (Fig. 1c) while
expression of CD42b/CD41 markers increased (Fig. 1d).
The fraction of CD42b/CD41 double positive events was
significantly lower in cultures from PB than in UCB on
D10, 11 & 12 (Fig. 1d) with a difference of 44 – 9% vs
76 – 11% CD42b/CD41 positive events on D12 for PB
and UCB, respectively (P < 00001).
Production of platelet-like particles
On D12 of culture, cells were perfused for two hours
resulting in cell anchorage, elongation and release of
PLP, starting from both UCB and PB (Fig. 2a and b). The
PLP yield defined as the number of PLP over the number
of input cells was significantly higher for PB (74 – 44)
than for UCB (42 – 22) (P = 002) (Fig. 2c). The PLP
yield was independent of the proportion of mature MK
when defined as events positive for CD41/CD42b present
in the input sample. This held for cells isolated from UCB
(r = -013, P = 062) (Fig. 2d) and from PB (r = 003,
P = 085) (Fig. 2e) at D12.
Platelet receptor expression
The fraction of events in the morphology gate (Fig. S1)
staining positive for either CD41, CD42b or both was
comparable between PLP from UCB or PB sources (Fig. 3a
and b). Consequently, based on our definition (Fig. S1)
approximately 60% of PLP could be defined as platelets
(Fig. 3c). Expression of CD61 was also comparable
between both HSC sources (Fig. 3d). The mean number of
CD42b, CD61 and CD49b receptors per PLP did not signif-
icantly differ between both stem cell sources and is com-
parable to the number of receptors on bPLT (Fig. 4). The
number of CD42b receptors per PLP is on average 28 000
per PLP (Fig. 4a) while this is approximately 57 000 and
5500 per PLP for CD61 and CD49b, respectively (Fig. 4b
and c).
Morphology and cytoskeleton stain
Cell suspensions after perfusion were analysed by DIC
microscopy at 10009 magnification. All suspensions
contained a heterogeneous cell population by size. Par-
ticles structurally comparable to platelets were found
both in UCB and PB derived samples (Fig. 5a and b).
These contained what appeared to be granules as
intense dark zones inside and near the cell’s periphery.
Alongside these, the suspension also contained large
cells (*) characteristic of remainder MK. The ratio of
remaining MK compared to PLP was approximately 7:3
and was indistinguishable between UCB or PB. Particles
smaller than typical platelets could either be extracellu-
lar vesicles (also called microparticles) or cell debris.
Reference bPLT were prepared as a control sample
(Fig. 5c). Additionally, the cytoskeleton protein actin
was visualized on the DIC images (Fig. S2). All cells
from the bPLT suspension stained positive for actin
while in the cell suspension from UCB only particles
with comparable structure to platelets were found posi-
tive for actin.
Table 1 Absolute number of total nucleated cells before isolation and of CD34+ cells after isolation from PB or UCB
UCB PB
Absolute number of total nucleated cells per sample before isolation (9108) 149 – 065 693 – 173
Absolute number of CD34+ cells per sample after isolation (9105) 1697 – 649 393 – 135
Data are shown as mean – SD (n ≥ 14).
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Discussion
To manufacture platelets in vitro, three major steps are
needed [28]: first, appropriate stem cells are expanded in
tissue culture. In a second step, these are differentiated to
generate haematopoietic and MK precursor cells. As an
alternative, immortalized MK can be used as demon-
strated by Nakamura et al. [11]. In any case, the final step
is to produce platelets from these MK in an efficient and
safe manner.
Ultimately, the technology will use self-renewable stem
cell sources like hESC or iPSC although some advocate
the use of UCB and PB as well [29]. Ethical concerns limit
the use of hESC [30] and current platelet yields obtained
from iPSC are not (yet) reaching platelet yields obtained
in vivo [5, 10, 11, 31]. Therefore, to enable research and
development to the final step in the process (platelet pro-
duction), primary HSC can still be used and offer an inex-
pensive and accessible source. Furthermore, for rare
phenotypes, PB may still be needed as a source of autolo-
gous stem cells. Bearing this in mind, this study’s objec-
tive was to compare the yield and quality of platelets
produced in hydrodynamic flow conditions using precur-
sor cells from either UCB or PB and to compare these to
current standard of care bPLT.
As expected from research by van den Oudenrijn et al.
[13], in vitro expansion of stem cells in static conditions
was more efficient from UCB than from PB. Relative to
D0, a 68-fold and 32-fold expansion was found on D7
for UCB and PB, respectively. From D7 on, the TPO con-
centration was raised to promote differentiation to MK. In
those conditions, platelet production happens sponta-
neously, albeit slowly and asynchronously [16, 32, 33]. In
our flow chambers, the combination of shear and immo-
bilized VWF results in synchronized and efficient platelet
production [14, 27]. BSA gradient centrifugation was per-
formed on culture cell prior to perfusion in the flow
chamber to remove PLP produced during static culture
Fig. 1 Static cell culture of HSC derived from PB or UCB. (a) The percentage HSC obtained by magnetic isolation per total nucleated cells in UCB (□) or
PB (●) samples. (b) The proliferation (all cells), in function of time, expressed as fold increase relative to the number of cells seeded on D0. (c) Expression
of CD34 and (d) CD42b/CD41 markers on cultured cells as measured by ﬂow cytometry as a function of time. Data are shown as mean with SD (n ≥ 5).
Statistical analysis results are shown as *P < 005, **P < 001, ***P < 0001 and ****P < 00001.
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conditions and focus investigation on PLP produced in
the flow chamber. When comparing precursor cells
sourced from UCB and PB, a higher platelet yield for PB
was found. These data are comparable to findings in sta-
tic conditions [19]. Hence, phenotypic differences between
source cells are translated in the same way in static as in
dynamic conditions. MK ploidy has been suggested to
correlate with platelet production [19], albeit not in all
conditions [34, 35]. We hypothesized that the fraction of
CD42b/CD41 positive MK in the input suspension could
predict PLP yield but the data show this was not the case.
Consequently, although these markers are specific for pla-
telets, these do not predict platelet production efficiency
in our system. But expression of CD42b/CD41 as a predic-
tor for PLP production cannot be ruled out completely
because the exact expression levels of CD42b/CD41 on
the MK may still be correlating. Despite differences in
HSC expansion and platelet production efficiency, platelet
phenotypic characteristics are quite similar between UCB
and PB. Foremost, these are also comparable to standard
bPLT, although a trend was found for lower GPIba
(CD42b) and higher integrin b3 (CD61 or GPIIIa) expres-
sion. Decreased GPIba expression levels have also been
reported in murine platelets produced in vitro in static
conditions from mouse ESC [36]. This was caused by
ectodomain shedding and could be prevented by co-incu-
bation with a metalloproteinase inhibitor. Importantly,
GPIba levels were not decreased to levels relevant to
impede haemostasis [37]. Contrary to GPIba, an increase
in integrin b3 expression was found. The b3 integrin
dynamically forms heterodimers with aIIb and aV, the for-
mer being utmost important for platelet aggregation as
the fibrinogen receptor. Platelet aggregation studies are
required next to demonstrate whether this moderate
increase translates into altered function compared with
bPLT.
Fig. 2 Platelet production in hydrodynamic ﬂow. (a) Representative image of cell anchorage (*) to VWF-coated pillars (white dots) of a cultured cell
(D12) started from UCB and (b) PB. Cell elongation and (pro)platelet formation is indicated by red arrows. The ﬂow direction is shown by a white arrow.
(c) The number of PLP produced per input cell during the perfusion experiment. Data are given as mean with SD (n ≥ 12). Statistical analysis results are
shown as *P < 005. (d and e) The PLP yield was plotted as a function of the number of CD42b/CD41 double positive input cells for (d) UCB (n = 36)
and (e) PB (n = 13).
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Fig. 3 Expression of platelet markers. The fraction of PLP that was staining positive for (a) CD42b, (b) CD41, (c) CD42b/CD41 and (d) CD61 produced
from UCB (open bars) and PB (closed bars). Data are shown as mean with SD (n ≥ 5).
Fig. 4 Number of platelet receptors. The number of (a) CD42b, (b) CD61 and (c) CD49b receptors was determined using GP screen kit on PLP produced
from UCB (open bars) and PB (closed bars). Data were compared to the levels in bPLT (hatched bars). Data are shown as mean with SD (n = 4).
© 2019 The Authors.
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The input cell suspension contains MK in several stages
of maturation [33, 38, 39] and senescence. After the 2 h
of perfusion to produce platelets, a double centrifugation
is performed to remove remainder MK and concentrate
PLP. Our microscopic images indicate that large cells as
well as small particles are nonetheless still found. Using
flow cytometry, a fraction of 70% was consequently
defined as platelets while the other 30% are remaining
MK (with exclusion cellular debris and microparticles).
The same ratio of PLP and MK was found in the micro-
scopic images for both UCB and PB. Therefore, future
clinical applications will require optimized filtration and
concentration steps of the outflow [40]. Such alternatives
are spinning-membrane filtration devices [41] or
microfluidic-based separations whether or not in combi-
nation with acoustopheresis [42].
However, the microscopic images indicate mainly pla-
telet-like cells. These are similar in size and aspect to
bPLT with this imaging technique. These platelet-like par-
ticles were present in both suspensions from UCB and PB.
Furthermore, actin staining showed that these platelet-like
cells are positively stained while no actin was detected in
smaller particles. Ultrastructural analyses using electron
microscopy must be used to further identify the subcellu-
lar organelles as alpha and/or dense granules characteris-
tic of healthy platelets.
We conclude that platelet production efficiency by per-
fusion of cultured cells in VWF-coated microfluidic flow
chambers is higher starting from PB compared to UCB,
like in static conditions. Despite this, the absolute over-
all PLP number is higher starting from UCB because of
higher number of isolated cells and higher proliferation
rates in the preceding static culture. Preliminary platelet
characterization indicates surface receptor expression
and morphology are comparable to reference bPLT.
Future experiments should focus on platelet
ultrastructure and platelet function. In the long run,
increasing the platelet yield and lowering produc-
tion costs are essential prior to proceeding to clinical
trials comparing these in vitro produced platelets to
standard PC.
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Fig. S1 Representative scatter plots to define PLP and platelets.
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